Moderna Therapeutics

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.

Moderna has developed a broad intellectual property estate including more than 250 patent applications covering novel nucleotide chemistries and drug compositions. The company plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as new formed ventures.

Type
Private
HQ
Cambridge, US
Employees
380 (est)+3%

Key People at Moderna Therapeutics

Stephen Hoge

Stephen Hoge

President
Noubar Afeyan

Noubar Afeyan

Chairman & Co-Founder
Stephane Bancel

Stephane Bancel

CEO
Lorence Kim

Lorence Kim

CFO
Steve Harbin

Steve Harbin

SVP of Human Resources & Clinical Supply Operations
Marcello Damiani

Marcello Damiani

Chief Digital Officer

Moderna Therapeutics Locations

Cambridge, US
Cambridge, US
Huddinge, SE

Moderna Therapeutics Metrics

Moderna Therapeutics Summary

Market valuation

$3 B

Total Funding

$1.1 B

Latest funding size

$8 M

Time since last funding

3 months

Investors

Moderna Therapeutics Online Presence

Moderna Therapeutics News

Moderna Therapeutics Company Life

You may also be interested in